TREATMENT. Active surveillance in intermediate risk prostate cancer.

CONCLUSION: Active surveillance for men at the favorable end of intermediate risk prostate cancer is an appealing alternative to radical therapy, but carries amodest but increased risk of metastatic disease compared to low risk cancer. Many biomarkers are currently being evaluated to enhance precise risk stratification of this important subgroup of patients. PMID: 30855017 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30855017?dopt=Abstract

Source: Archivos Espanoles de Urologia - March 12, 2019 Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research